INVIVO THERAPEUTICS HOLDINGS CORP. Form 10-Q May 07, 2015 Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2015

or

0 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

to

.

Commission File Number: 001-37350

InVivo Therapeutics Holdings Corp.

(Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of

incorporation or organization)

One Kendall Square

Suite B14402

Cambridge, MA (Address of principal executive offices)

(617) 863-5500

(Registrant s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

Large accelerated filer o

Non-accelerated filer o (Do not check if a smaller reporting company) Accelerated filer x

Smaller reporting company o

02139 (Zip code)

36-4528166

(I.R.S. Employer

Identification Number)

Edgar Filing: INVIVO THERAPEUTICS HOLDINGS CORP. - Form 10-Q

As of April 30, 2015, 26,561,815 shares of the registrant s common stock, \$0.00001 par value, were issued and outstanding.

Table of Contents

INVIVO THERAPEUTICS HOLDINGS CORP.

Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2015

TABLE OF CONTENTS

<u>PART I</u>	Page 3
FINANCIAL INFORMATION	3
1. Financial Statements (Unaudited)	3
Consolidated Balance Sheets as of March 31, 2015 and December 31, 2014	3
Consolidated Statements of Operations for the Three Months Ended March 31, 2015 and 2014	4
Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2015 and 2014	5
Notes to Consolidated Financial Statements	7
2. Management s Discussion and Analysis of Financial Condition and Results of Operations	14
3. Quantitative and Qualitative Disclosures about Market Risk	18
4. Controls and Procedures	18
<u>PART II</u>	18
OTHER INFORMATION	18
1. Legal Proceedings	18
1A. Risk Factors	19
2. Unregistered Sales of Equity Securities and Use of Proceeds	19
3. Defaults Upon Senior Securities	19
4. Mine Safety Disclosures	19
5. Other Information	19
<u>6. Exhibits</u>	19

2

Table of Contents

PART I FINANCIAL INFORMATION

SPECIAL NOTE

All share number and share prices presented in this Quarterly Report on Form 10-Q have been adjusted to reflect the 1-for-4 reverse stock split of InVivo Therapeutics Holdings Corp. s common stock effected on April 8, 2015.

Item 1. Financial Statements.

InVivo Therapeutics Holdings Corp.

Consolidated Balance Sheets

(In thousands, except share and per-share data)

(Unaudited)

	As of		
	<i>,</i>	D	ecember 31, 2014
\$	24 516	\$	13,459
Ψ	,	ψ	422
			1,072
			14,953
	25,420		14,955
	1,431		1,605
	130		135
\$	26,981	\$	16,693
\$.,	\$	569
	320		320
			18
			7,224
	1,364		1,044
	15,121		9,175
	\$	March 31, 2015 \$ 24,516 361 543 25,420 1,431 130 \$ 26,981 \$ 26,981 \$ 793 320 12,644 1,364	March 31, 2015 S 24,516 \$ 361 543 25,420 1,431 130 S 26,981 \$ S 793 \$ 320 12,644 1,364

Edgar Filing: INVIVO THERAPEUTICS HOLDINGS CORP. - Form 10-Q

Loan payable	1,600	1,600
Total liabilities	16,721	10,775
Commitments and contingencies		
Stockholders equity:		
Common stock, \$0.00001 par value, authorized 50,000,000 shares; issued and outstanding		
26,011,852 and 23,453,000 shares at March 31, 2015 and December 31, 2014,		
respectively.	1	1
Additional paid-in capital	126,344	106,172
Accumulated deficit	(116,085)	(100,255)
Total stockholders equity	10,260	5,918
Total liabilities and stockholders equity	\$ 26,981 \$	16,693

See notes to the unaudited consolidated financial statements.

(Reflects 1-for-4 reverse stock split effective April 8, 2015)

Table of Contents

InVivo Therapeutics Holdings Corp.

Consolidated Statements of Operations

(In thousands, except share and per-share data)

(Unaudited)

	Three Mon Marc 2015	ed 2014
Operating expenses:		
Research and development	\$ 2,303	\$ 3,242
General and administrative	3,208	1,829
Total operating expenses	5,511	5,071
Operating loss	(5,511)	(5,071)
Other income (expense):		
Interest income	1	1
Interest expense	(34)	(33)
Derivatives gain (loss)	(10,286)	
Other income (expense), net	(10,319)	(32)
Net loss	\$ (15,830)	\$ (5,103)
Net loss per share, basic	\$ (0.64)	\$ (0.28)

Net loss per share, diluted